WO2013050526A1 - Device and method for selecting active ingredient candidates - Google Patents

Abstract

The invention relates to an administration device, an administration method and use thereof for selecting one or more active ingredient candidates from the group of active ingredients in a data base and a system for identifying suitable active ingredient candidates of all development stages for pharmaceutical development based on development-specific type and admission relevant data sets in relation to said active ingredient candidates, in addition to the efficient exchange between providers and buyers.

Description

 Apparatus and method for selecting drug candidates

The invention relates to a management device, a management method and their

Use for selecting one or more drug candidates from a group of drugs in a database and a system for identifying suitable drug candidates of all

 Development stages for drug development on the basis of development stage-typical as well as registration-relevant data sets for these drug candidates, as well as their efficient mediation between provider and buyer.

State of the art

 Before a new drug enters the market, its precursors - here as

Drug candidates referred - usually changed at least once the owner or rights holder. Due to the necessary innovation, the necessary and financially intensive development steps as well as the long development times for new drugs, the phase of finding a new drug candidate, right through to approval as a new drug, rarely takes place within a single organization. Rather, drug candidates are often sold or licensed by a provider to a buyer on their way to the drug. On the way to approval, a buyer can become a supplier again, with or without passing through selected development phases for the drug candidate.

Methods are described in the art for suitable drug candidates

identify, evaluate and communicate:

 a) business development and licensing departments of the provider and the buyer side, b) internet-based offer platforms, as well as

 c) so-called "Partnering Conferences".

It is disadvantageous to all three methods that the offered and the requested data become one

Drug candidates are not standardized, that the staff and time, especially in (a) and (c) is very high and that the conclusion of a commercial agreement is not prepared and carried out efficiently.

 The description in particular offered drug candidates is shaped very individually to the current state of the art. The vendor selectively emphasizes the benefits of its drug candidate, while unfavorable or missing data are slow to detect, or even unrecognizable on demand. The free text format, the personal one

Dominated by each other as well as in Internet-based communication platforms, supports this disadvantage, which leads to high efficiency losses in the business initiation or finally completely prevents the commercial agreement. One prior art system is DrugBank [Wishart et al., 2006, "Drag Bank: A Comprehensive Resource for In-Silico Drag Discovery and Exploration", Nucleic Acids Research, Vol. 34 D668-D672], which is a database DrugBank is used to gain insight into the in-silico design of drugs based on well-known substance structures and targets, as well as other pharmacological and drug discovery properties

Development potential of a substance make up, however, are not described or only inadequately or qualitatively. First and foremost, data are included which should help to investigate structural properties of a substance or to understand its interaction with the respective target. The search is carried out according to the respective substance. Upon successful search, the respective properties of the substance are then output. That is, the seeker must already know a substance whose properties he wants to read. However, it is not possible to search for desired properties and thus arrive at a suitable drug candidate. The divestiture or licensing of therapeutic drug candidates today is typically a process that is initiated, processed and completed directly between providers (e.g., licensors) and buyers (e.g., licensees). In addition to own activities of providers and buyers from their respective organizations, the preferred medium for this is so-called "partnering".

Conferences (for example the conferences BIO, BioEurope, BioPartnering, etc.), in which so-called one-on-one discussions organize vendors and buyers in terms of schedule and sector (by the

Conference organizers) and exchange views on the respective drug candidate. In the wake of these Erstgesprächen find more meetings, possibly a due diligence and

Contract negotiations before licensing occurs; The entire process usually takes 9-15 months. Due to a constant need for financing as well as an intensive competition in the market the licensing offers very often lack the necessary objectivity, completeness and comparability, which must be worked out in often lengthy discussions with the potential buyer. In addition, the initially involved buyer side does not always have the necessary know-how to fully value an asset. The lack of objectification and standardization of the offer is also due to the current Internet-based offering platforms, such as those offered in the life science sector by, for example, Innovaro or Bioinnovit for drug candidates. Again, it is up to the provider, as his drug candidate is presented and described; therefore, he often misses the information request that a potential buyer has and prevents or at least slows down the desired sale process. The current internet-based Offer platforms are primarily designed to be provider-friendly, the required buyer-friendly concept has not been developed so far.

The object of the invention is accordingly, an apparatus, a method and a system

to provide that does not have the disadvantages or deficiencies of the prior art.

description

The problem is solved by the independent claims. Advantageous embodiments can be found in the dependent claims.

In a first preferred embodiment, the invention relates to a drug candidate selection management device connected to at least one user front-end and at least one provider front-end, the device comprising a. a database application connected to a data acquisition application

 Collect parameter values and maturity level of drug candidates in datasets that have been submitted by at least one provider front-end, where b. at least one destination parameter is detected by the user front-end, wherein the

 Ranking can be determined by detecting more than one target parameter and wherein the target parameter can also be an exclusion criterion, where c. is queried via the database application of the target parameters in the records, where d. a list is created, the drug candidates with parameter values to the

 Matching and matching target parameters, where e. an output unit sends at least one output message to at least one front end, where f. the output message comprises the list and at least data enabling contact making to the provider front-end via which the parameter values of the drug candidates were submitted from the list.

This embodiment has many advantages over the prior art. The new

Management device allows the search for specific properties on the parameter values, so that the drug candidate does not have to be known in advance. Thus, it becomes possible to select an appropriate drug candidate by searching for desirable properties. With the management device according to the invention is for the first time a standardized Search possible. Not only are the search criteria, in particular the target parameters, standardized, but also the data sets concerning the drug candidates. This makes the search for a suitable drug candidate more efficient and, above all, takes significantly less time compared to devices and methods of the prior art. For the purposes of the invention, "matching one another" means in particular that the parameter values of the

Drug candidates match the target parameters and / or search criteria. However, it is also preferred that deviations in a defined tolerance range are evaluated as "mutually compatible." It is also advantageous that the target parameters and / or search criteria specify a range and drug candidates are included in the list whose parameter values lie in these ranges There is a tolerance range on both sides of the selected area.

For the purposes of the invention, the term front-end refers to a location in connection with a stratification, which is a location that is closer to the user, provider and / or the input. In particular, this may be a program running on the client, a user interface, preferably a graphical user interface consisting of input masks, forms and / or reports and / or a web page accessible to the public.

The provider front-end is preferably serviced by a vendor who inputs information about a drug candidate. This information is preferably collected as standardized data in records. It is particularly preferred that the provider enters the information in a given mask, as this facilitates the standardization.

The user front-end is preferably serviced by a user, most preferably by a potential buyer searching for a drug candidate. The user may preferably select or enter search criteria and / or destination parameters. It is preferred that the database application comprise a drug candidate comparison matrix.

It is preferred that contact information be communicated with the list of drug candidates that enable contact to be made with the provider front-end. This can be done either by a direct contact, for example, by providing contact details such as e-mail address, address or telephone number. However, it is also preferred that the management device has its own training service, via which a

Notification will be sent. In addition, it is advantageous that a cipher system is used, via which the contact is initiated. This embodiment is advantageous since the provider or the user can initially remain anonymous. In another preferred embodiment, the invention relates to a database usage management method for selecting drug candidates wherein at least one user front-end and at least one provider front-end are associated with a management device according to claim 1, comprising the following steps: g. Collecting data on drug candidates, in particular parameter values and degree of ripeness, h. automated quality control of data, i. Publication of data on the drug candidates, j. Entering search criteria, whereby the search criteria are preferably stored, k. Matching the search criteria with the data on drug candidates, 1. Finding selected drug candidates whose parameter values match the search criteria, m. Sorting of the selected drug candidates, preferably according to the maturity levels.

The method makes it possible to make a very accurate selection of a suitable drug candidate. The automated quality control checks whether the datasets concerning the active substance candidates meet the requirements of the requested parameters. This avoids inaccurate information and ensures a high quality of the procedure. Only when the quality control has been completed with a positive result will the data be published in the database. If the data does not yet meet the requirements, these must be revised and sent again. After publishing, the database application can access the data for a query of the search criteria and / or destination parameters. Thus, the output of erroneous

Results, further contributing to the efficiency of the process.

Also preferred is the management device and / or the management method, wherein the target parameters are selected from the group comprising disease, molecular group comprising protein, small molecule, natural product, nucleic acid and / or synthetic molecule, properties of a molecule comprising biochemical, physical, chemical, physicochemical , cellular, disease-specific, pharmacological, pharmacokinetic, toxicological and / or synthetic properties or synthesis of a molecule.

It is preferable that the data is collected on a storage medium or a data storage. Also preferred is the management device and / or the method of administration, wherein the drug candidate is a chemical or biological molecule, combinations of which are preferred. It may also be advantageous for the candidate to be a physical molecule.

Advantageously, it is possible to show or hide the structure of the candidate, in particular the chemical structure, on the output unit. The output device or the output unit may be, for example, a monitor connected to the client. However, this may also be a smartphone or other electrical device with an output unit.

In a further preferred embodiment, the invention relates to the management device and / or the administration method, wherein the degree of maturity is selected from the group comprising hit molecule, improved hit, lead candidate, lead, preclinical

 Development candidate, active substance in preclinical development, clinical development candidate, phase 1 active substance, phase 2a active substance, phase 2b active substance, phase 3 active substance, approval for a new drug and / or authorized drug.

The degree of maturity preferably describes the development phase of a drug candidate. For the purposes of the invention, the development of a drug candidate in different phases or

Maturity levels are classified, namely:

1. Hit Molecule (H): In this phase, there is a result of a drug discovery process. This can be the confirmation of a hit molecule, the establishment of a structure-function relationship by other hit molecules, the proof of the power of the hit by IC50 data, a pure finding process without chemical variations on the hit molecule or the availability by re-synthesis of the hit molecule.

2. Improved hit (vH): In this phase, the first chemical variations on the hit molecule improved its potential. In addition, biochemical and cellular data, but no animal model data, may be available. 3. Lead Candidate (LK): Data from disease-specific and pharmacological animal models are available at this stage and the candidates are in one

Medicinal chemistry program.

4. Lead molecule (L): At this stage of maturity, the completion of the medicinal chemistry program has been completed.

5. Preclinical Developmental Candidate (PEK): In this phase, a large-scale synthetic route for the drug candidate has already been developed. A pharmaceutical

Development program is completed (salt selection, stability program, dosage form, etc.) and chemical changes more to the molecule are no longer provided, but still possible. 6. Active substance in preclinical development (WpE): At this stage of maturity, the preclinical development program has already started. There will be no more variations on the molecule. The goal is now the official registration and registration of a new clinical development candidate. 7. Clinical Development Candidate (CEC): At this stage, there is an officially registered, registered and approved candidate for clinical development. Phase I may already have started.

8. Phase I Drug (PI): Phase I clinical development has been completed with this

Drug candidates have already passed successfully. Phase IIa may already have started.

Phase IIa drug (P2a): Phase IIa of clinical development has been completed with this

Drug candidates have already passed successfully. Phase IIb may already have started.

Phase IIb Drug (P2b): Phase IIb of clinical development was completed with this

Drug candidates have already passed successfully. Phase III may already have started. 1 Phase III Drug (P3): Phase III clinical development has been completed with this

 Drug candidates have already passed successfully. Registration as a new medicine may already have started.

12. New drug application (ZNA): At this stage, all the data for the application for authorization is available. The contact with the authorities is imminent or has already taken place.

13. Authorized medicinal product (ZA): An approved medicinal product is in this phase.

The information about the respective degree of maturity of a drug candidate is of particular importance for the selection of a suitable drug candidate. So far, it has not been possible to retrieve this information in standardized form. The maturity levels mentioned are preferred. However, this is not a completed list. It can be added more maturity levels.

It is preferred that a list of at least 2 drug candidates is displayed on the dispensing unit. In the context of the invention, a list denotes, in particular, a ranking of

Drug candidates according to the entered and / or selected target parameters. The order or the sorting of the drug candidates in the list is preferably carried out according to the respective

Maturity levels. It is preferred that the order either for descending levels of ripeness (from 12. ZA to 1. H) or for ascending levels of ripeness (from 1. H to 12. ZA). However, other sorting criteria can also be specified. In each phase, the drug candidate can be described by characteristic parameters and corresponding parameter values. Further preferred is the management device and / or the administration method, wherein the parameter values relate to physical, chemical and / or biological properties of the drug candidate. The following parameters are preferred: For the phase of the hit molecule (H), especially molecular parameters are preferred, eg

 Molecular weight, log P, log D, solubility in DMSO in mg / ml, solubility in ethyl alcohol in mg / ml, solubility in 50 mM Tris buffer pH 7.4 in mg / ml, water solubility in mg / ml,

Molecular surface in Ä ² , number of hydrogen donors, number of hydrogen acceptors, Lipinski rules met. In addition, the specification of synthesis parameters is preferred, eg recoverability of the active ingredient, described synthesis route. Furthermore, typical screening as well as biochemical parameters are advantageous, eg multiple finding of the hit molecule in the screen, independent

Confirmation of the target molecule, potency of the molecule in the biochemical test (IC50), potency of the molecule in the cellular test (IC50), potency of the molecule in the phenotypic test (IC50), structure-effect relationship derivable from first hit molecules, number of the first

Hit population, availability of specificity data, availability of specificity data in

Comparison to the nearest related target molecules. In addition, parameters of the test system are preferred, e.g. Existence of another biochemical test system, presence of a cellular test system, presence of a phenotypic test system, targeting pathway, targeting mechanism.

For the enhanced hit (vH) phase, in addition to the preferred parameters for the phase of the hit molecule, the following are added in particular. Especially preferred are parameters about the synthesis parameter, e.g. Availability of supply of starting materials, awareness and / or availability of the synthetic route, number of synthetic steps, presence of a confirmed structure-function relationship, number of compounds in this hit population, presence of an identified IP barrier. For the phase of the lead molecule candidate (LK) and of the lead molecule (L), the following are added to the already mentioned parameters for H and vH: They are above all

disease-specific parameters are preferred, e.g. Strength in the primary cell test system, potency on the isolated organ, where each organ can be selected, potency in the animal

Disease model, where each disease model can be selected. Also, parameters about specificity data are preferred, e.g. Strength compared to a specific one

Molecule, where each molecule can be selected or there is a pre-selection of molecules to choose from. In addition, ADMET parameters are preferred, e.g.

Inhibition of a particular enzyme, where any enzyme can be selected or there is a pre-selection of enzymes to choose from eg p450 2D6 or p450 3A4, CaCo2 cell penetration, MDCK cell penetration, cell-based HERG inhibition , Existence of organ-based HERG inhibition. Also, in Pharmacological parameters particularly preferred for this phase, eg maximum plasma concentration, achievement of the maximum plasma concentration, presence of an albumin bond, number of available back-up compounds.

For the phase of pre-clinical development (PDC), the following are added to the already mentioned parameters for H, vH, LC and L: Particular preference is given to the parameters of the selected salt of the compound and / or the chosen formulation. Furthermore, parameters relating to stability are preferred, e.g. Temperature stability in% of the original.

For the phase of the active substance in pre-clinical development (CpD), the following are added to the already mentioned parameters for H, vH, LC, L and PDC: Preference is given in this phase to parameters for safety pharmacology. There are also parameters for

Toxicology, e.g. Heart rate in a given species, history of liver transaminases in a particular species.

The parameter value can be either a number or a specific name. However, parameter values are also preferred for which there is a yes / no selection. It is preferred that the data sets relating to the drug candidates also include data relevant to a possible licensing and / or market entry of the drug candidate.

It is preferred that these parameter values be specified as destination parameters or search criteria for the selection. It is preferred that there is a hierarchical structure of the target parameters and / or search criteria. For example, selecting a specific destination parameter causes a subselection to be made. This surprisingly leads to a significant increase in the selection of suitable drug candidates and thus to a greater "yield" of the process.

In a further preferred embodiment, the invention relates to a use of

Administrative device and / or administrative procedure for selecting a

Drug candidate from a group of drug candidates in a database, comprising the following steps: n. Acquisition of at least one target parameter, o. Implementation of a database application, wherein the target parameters in a database

 comprising data sets comprising parameter values for a group of drug candidates

P- Create a list in which the drug candidates are included with parameter values that match the target parameters. In a further preferred embodiment, the invention relates to a system for switching at least one drug candidate, comprising a database, which data on

Drug candidates, in particular parameter values and ripeness, containing on a

Storage medium is stored on a service provider, where q. a user makes a manual input or selection of at least one destination parameter in a search mask on a client via at least one input unit and one output unit, wherein a plurality of target parameters can be selected by means of and / or linkage, r. a digital network is established between the one client and a service provider, s. at least one drug candidate in the database is determined on the service provider having the at least one selected target parameter, t. Display of at least the one in s. identified drug candidates on one

 Output device.

Further preferred is the system wherein the active agent is a chemical or biological molecule.

In addition, the use of the system for the identification and mediation of

Drug candidates between at least two users preferred.

Surprisingly, a system can be provided by the invention, which does not have the disadvantages and deficiencies of the prior art and an objectification, completion and production of an internationally valid comparability of the offered reliable

 Information allows so that drug candidates can be selectively researched and compared. In addition, a ranking of the drug candidates is possible.

Also preferred is the system wherein the user is selected from the group comprising system operators, buyers or sellers. A user is preferably a system operator, buyer or seller. The drug candidate is preferably selected from the group comprising a hit molecule, improved hit, lead candidate, lead, preclinical candidate, clinical development candidate or drug.

The drug candidate may advantageously be a chemical or biological molecule. It is preferred that the target parameters include chemical, biological and / or physical properties of the drug candidate. Furthermore, it is preferred that the system runs automatically, in particular fully automatically. Thus, the system is less error prone and a selection can be made faster.

The system may preferably be used for the identification of drug candidates and mediation between at least one user with a provider. The storage medium or a data storage serves for the purposes of the invention for the storage of data or information, in particular parameters, parameter values and maturity levels of drug candidates. The data can advantageously be supplemented at any time by more and are preferably in digital form. It may be preferred that the storage medium is a mass storage device with preferably magnetic recording technology or semiconductor memory technology or a flash memory. A mass memory referred to in the context of the invention

 Storage medium, which stores a large amount of data or information preferably over a longer period. Advantageously, a mass storage with magnetic

Be used to write binary data on the surface of a rotating, ferromagnetic disk. Semiconductor memory are in the context of the invention data storage, which consist of a semiconductor, are realized in the integrated circuits by means of semiconductor technology. The data is stored in the form of binary electronic switching states in the integrated circuits. This enables permanent and secure safekeeping as well as easy administration of the data.

 The present system, management method and / or management device standardizes both the data and / or the data set for offered drug candidates and their search along the target parameters, which are relevant for admission to the clinic or the market, or for selected stages of development ( Maturity levels) and / or disease indications are typical, especially in the preclinical area (eg hit, profiled hit, lead candidate, lead, preclinical development candidate, IND, and others). This allows for early, factual and comprehensive insight into the drug profile of properties, a quick and comparative assessment of the therapeutic potential of the substance from the point of view of the prospective buyer, including the automatic ranking of hits during a query, as well as efficient preparation on any negotiations. In order to support the last point, the system presented here also provides process-related prerequisites on the supplier side (for example, prefabricated CDA, MTA, data room, draft contract) as well as information relevant to evaluation (for example market studies, IP analysis, comparative analyzes,

Value calculations). It was surprising how much efficiency this system offers in terms of a commercial agreement between the supplier and the buyer, and thus also in terms of efficient drug development.

This results in a content-driven increase in efficiency in the licensing process, which is particularly desired by the buyer (especially in the pharmaceutical sector). It was completely surprising that successful licensing by the invention was already possible after 2-3 months. With the help of a cipher principle and / or its own notification service, the anonymity of the seller and the buyer is maintained for a sufficiently long time, thereby profiling the role of the system operator as an intermediary. In particular, the dataset on a potential drug candidate also conforms to criteria that are typical for the buyer market or that are based on international licensing standards, in line with its development phase.

ideally, they are populated with scientific benchmarks or selected comparative examples (e.g., approved drugs). Drug structures are preferably on

Supplier side can be faded in or out, in order to be able to patent the offered one

To maintain drug candidates. The hardware and software used is preferably quality-tested and proven ("Intel inside" principle). It is particularly advantageous that the hardware and software have a high degree of flexibility, as the system can thus operate very dynamically - both on the provider side and also in terms of the parameter space used to sufficiently characterize the drug candidate.

It is preferred that the system be extended to the analytical precursor and product market, the biomarker area, and the life science services sector. Because the system of the invention can also be applied to these areas and lead to the advantages of the invention.

The principle of authorization- and buyer-driven description of the asset while maintaining its (further) patentability is also preferred embodiment of the system. A buyer will put together an individual query from a series of "pull-down-menues" and send it to the system, which then automatically calculates a ranking of the buyer according to the buyer's specifications

selected drug candidates produced; the selected drug candidates are underpinned with additional data. Even in the case of services, such a system is conceivable with an adequate description of the service while preserving the know-how of the provider.

Also preferred is a method for selecting an active substance candidate from a group of active substances in a database, comprising the steps: viii Manual input and / or selection of at least one parameter in one

 Search mask on a client via at least one input unit and one

Output unit, wherein a plurality of parameters can be selected by a and / or link, ix establishing a digital network between the one client and a service provider, x Searching in a database in a storage medium on the service provider for at least one candidate that has the at least one selected parameter, xi Display of at least one in x. identified candidates on the output device. It is preferred that the parameters include physical, chemical and / or biological properties of the drug candidate.

In the following, a preferred embodiment of the invention will be explained with reference to an example, but without being limited thereto. A potential buyer (e.g., pharmaceutical or biotech companies) is looking for a preclinical

Development candidates in the indication Diabetes II to complete his own

Development pipeline.

The potential buyer fills in a request in which various parameters are optionally linked with "and", "or" or "and / or" The parameters can either be selected from an offered parameter list or preselected with ">" or "<" The result of a request can also be sorted according to any parameters to allow individual sorting.

example

Before at least one embodiment of the present invention is described in detail, it is to be understood that the invention is not limited in its application to the details of construction and arrangement of the example or figures. The invention may be further

Embodiments and it can be carried out in various ways. The expressions and terminology used are for description and are not

restricting to understand. In this example, the potential buyer selects from the disease parameter group.

 (Diseases), the proposed term "metabolic diseases" (Metabolie Diseases), other proposals would be, for example, cardiovascular diseases, diseases of the central nervous system or eye diseases (Cardiovascular Diseases, Diseases of the Central Nervous System or Eye Diseases) Indications that exist within the selected parameter "metabolic diseases", in the present example case of "diabetes II", including "diabetes I", "metabolic syndrome" (metabolic syndrome) or "phenylketonuria" (phenylketonuria) offered. The next parameter group is with

Overwritten "compound classes" and again offers a selection Parameters, for example, low molecular weight compound, antibodies, peptides, proteins, natural

Substances, DNA, (Small Molecule, Antibody, Peptides, Protein, Natural Compound, DNA) and others. For example, the potential buyer chooses "low molecular weight compound." Then, in the "compound properties" group, a selection of parameters is offered (eg, physicochemical, biochemical, cellular, in vitro ADMET, disease specific pharmacology, pharmacological safety, pharmacokinetics, toxicology , Synthesis, etc.

(Physicochemical, Biochemical, Cellular, in vitro ADMET, Disease-specific pharmacology, safety pharmacology, pharmacokinetics, toxicology, synthesis, etc.)), which are deposited one level lower with concrete data (eg under "physicochemical" is considered as Parameter "Solubility in Water" is given as 23 mg / ml). These values can either only be viewed by the buyer, but also searched for or called up in systemically or individually specified limits. Examples of other parameters within the parameter group "physicochemical" are "solubility in TRIS buffer pH 7.4", "solubility in DMSO", "surface of the molecule", "logD", "logP" (solubility in Tris buffer pH 7.4, solubility in DMSO, Surface Area of the Molecule, logD, logP) and others. In this way, a parameter profile is created for each drug candidate in each "disease" that is freely but automatically searchable.

Further parameter groups, which can be included in the search mask of the potential buyer at the beginning or later, are logistical or contractual supportive nature, eg "Exclusivity" with eg the parameter groups "IP", "Login areas" (Areas of Application), "Markets", or "Agreement Logistics" (Deal

Logistics) with e.g. the parameters "Availability of CDA", "Availability of MTA", "Market Reports", "Availability of

Dataroom "," Value Suggestions ", or" Provider Party "" Offering Party "with e.g. the parameters "Academic", "Public-Private Partnership", "Commercial", "Foundation" and others.

The prospective buyer's search (s) will result in a list of hits from the database, ordered either according to system specifications or individual buyer's preferences. If a buyer is an attractive hit identified, the buyer will contact the provider directly, if he has revealed his identity in the database, or according to the cipher principle

 Contact system operators to identify and eventually contact the provider. Following the contact, it is up to the supplier to label his drug candidate (e.g., "under negotiation") or until the trial ends

Contract negotiations unmarked in the system. The system is characterized by a high level of flexibility, as the provider can continuously set and edit data about his drug candidate via the system operator. Figure 1 shows a schematic representation of the conventional way of

Drug candidate selection. Particularly disadvantageous is the lack of standards, so that the process is carried out only inaccurate and is both personnel and costly.

A preferred embodiment of the invention is shown in FIG. Particularly advantageous is the standardized data transfer and the automated search for standard criteria, preferably target parameters and / or maturity levels. The automated ranking provides the user with clear and factual information about the selected drug candidates.

Figure 3 shows the WEB-specific parameter scope under Identification of

approval-relevant values. Figure 4 shows a subject data model of a preferred embodiment of the invention. The development stages are preferably maturation degrees in the sense of the invention.

Figure 5 shows a system map of a preferred embodiment of the invention.

Claims

Patent claims 1. Management device for the selection of active ingredient candidates which is connected to at least one user front end and at least one provider front end, the device comprising a. a database application connected to a data collection application for collecting parameter values and the maturity level of drug candidates into data sets, these parameter values being transmitted by at least one provider front end, wherein b. at least one target parameter is recorded by the user front end, whereby a ranking can be determined when more than one target parameter is recorded and where the target parameter can also be an exclusion criterion, whereby c. The target parameters in the data sets are queried via the database application, whereby d. a list is created that includes and orders active ingredient candidates with parameter values that match the target parameters, whereby e. an output unit sends at least one output message to at least one front end, f. the output message comprising the list and at least data that a Enable contact to be made to the provider front end through which the parameter values of the active ingredient candidates from the list were transmitted. 2. Management method for database use to select active ingredient candidates, wherein at least one user front end and at least one provider front end are connected to a management device according to claim 1, comprising the following steps: g. Collecting data about drug candidates, in particular parameter values and maturity level, h. automated quality control of the data, i. Publication of data on the drug candidates, j. Recording search criteria, whereby the search criteria are preferably saved, k. Comparing the search criteria with the data on drug candidates, 1. Finding selected active ingredient candidates whose parameter values match the search criteria, m. Sorting the selected active ingredient candidates, preferably according to the maturity levels. 3. Management device and/or management method according to claim 1 and/or 2, wherein the target parameters are selected from the group comprising disease, molecule group comprising protein, small molecule, natural product, nucleic acid and/or synthetic molecule, properties of a molecule comprising biochemical, physical , chemical, physicochemical, cellular, disease-specific, pharmacological, pharmacokinetic, toxicological and/or synthetic properties or synthesis of a molecule. 4. Management device and/or management method according to one or more of the preceding claims, wherein the active ingredient candidate is a chemical or biological molecule. 5. Management device and/or management method according to one or more of the preceding claims, wherein the parameter values relate to physical, chemical and/or biological properties of the active ingredient candidate. 6. Management device and/or management method according to one or more of the preceding claims, wherein the degree of maturity is selected from the group comprising hit molecule, improved hit, lead molecule candidate, lead molecule, preclinical Development candidate, active ingredient in preclinical development, clinical Development candidate, phase 1 active ingredient, phase 2a active ingredient, phase 2b active ingredient, phase 3 active ingredient, new drug approval and/or approved drug. 7. Use of the administrative device and/or administrative procedure at least one of the preceding claims for selecting an active ingredient candidate from a group of active ingredient candidates in a database, comprising the following steps: n. Detecting at least one target parameter, o. Carrying out a database application, the target parameters being in one Database comprising data sets containing parameter values for a group of drug candidates, which can be queried p. Creating a list containing the active ingredient candidates with parameter values that match the target parameters. 8. System for providing at least one active ingredient candidate, comprising a Database containing data about drug candidates, in particular parameter values and Maturity levels, which is stored on a storage medium on a service provider, where q. a user manually enters or selects at least one target parameter into a search mask on a client via at least one input unit and one output unit, with several target parameters being selectable by and/or linking, r. a digital network has been established between a client and a service provider, see at least one active ingredient candidate in the database on the service provider is determined, which has the at least one selected target parameter, t. Display of at least one active ingredient candidate identified in s. on an output device. 9. The system of claim 8, wherein the user is selected from the group comprising System operator, buyer or seller. 10. System according to one or more of the preceding claims, wherein the active ingredient is chemical or biological molecule. 1 1. System according to one or more of the preceding claims, wherein the system runs automatically. 12. Use of the system according to claims 8 to 1 1 for identification and Mediation of active ingredient candidates between at least two users.